Baxter International Inc. (BAX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Baxter International ( BAX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.5%. By the end of trading, Baxter International fell $4.56 (-6.4%) to $66.70 on heavy volume. Throughout the day, 13,237,370 shares of Baxter International exchanged hands as compared to its average daily volume of 2,592,900 shares. The stock ranged in price between $66.31-$69.79 after having opened the day at $69.79 as compared to the previous trading day's close of $71.26. Other companies within the Health Care sector that declined today were: Genvec ( GNVC), down 16.7%, KaloBios Pharmaceuticals ( KBIO), down 15.2%, AMAG Pharmaceuticals ( AMAG), down 14.3% and Clovis Oncology ( CLVS), down 11.6%.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.0 billion and is part of the health services industry. Shares are up 7.8% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, MAKO Surgical Corporation ( MAKO), up 82.2%, Pacific Biosciences of California ( PACB), up 72.8%, GW Pharmaceuticals PLC ADR ( GWPH), up 63.1% and Oncothyreon ( ONTY), up 21.1% , were all gainers within the health care sector with Catamaran ( CTRX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon